Fosun Pharmaceutical (02196): GR1803 injection was conditionally approved by the State Drug Administration

Zhitong Finance App News, Fosun Pharmaceutical (02196) announced that on May 28, 2026, Chongqing Yaoyou Pharmaceutical Co., Ltd. (hereinafter referred to as “Yaoyou Pharmaceutical”), a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as “Yaoyou Pharmaceutical”) signed a license agreement with Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. (including) licensed products (that is, bispecific antibody drugs targeting BCMA and CD3 with GR1803 as the sole active ingredient and/or agreed upon) in China, Hong Kong, Macao and Taiwan The exclusive right to clinical development and commercialization, as well as the exclusive right to research and production of production processes, will be used by Yakuyu Pharmaceutical as the marketing license holder (MAH) for this (etc.) product in the licensed region.

Recently, GR1803 injection (generic name: velitumimab injection, Chinese trade name: Victol®, hereinafter referred to as “this drug”) was conditionally approved by the State Drug Administration. The approved indication is for adult patients with recurrent or refractory multiple myeloma who have received at least previous third-line treatment (including a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody).

GR1803 is a bispecific antibody that binds both BCMA and CD3 antigens to redirect cytotoxic T cells to cells that express BCMA. In addition to the approved indications, as of the date of this announcement (i.e. August 27, 2026, same below), many clinical studies of this drug for the treatment of recurrent or refractory multiple myeloma and systemic lupus erythematosus in adults are being carried out in an orderly manner in China.

According to the latest IQVIA MIDAS TM data, the global sales volume of BCMA×CD3 target antibody drugs was approximately US$1,139 million in 2025. As of the date of this announcement, 2 BCMA×CD3 target antibody drugs have been conditionally approved for marketing in China, namely Pfizer Inc.'s enatumab injection (approved for marketing in March 2025) and Janssen-Cilag International NV's teritumab injection (approved for marketing in June 2024).

The drug has now been approved for marketing, and can provide new treatment options for adult patients with recurrent or refractory multiple myeloma in China, and will further enrich the product line of the Group (that is, the Company and its holding subsidiaries/units). Subsequently, Yaoyou Pharmaceutical and Zhixiang Jintai will proceed with the change of marketing license holder (MAH) for the drug in accordance with the agreement.